vor 4 Jahren

DGAP-Adhoc: Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2

DGAP-Ad-hoc: Formycon AG / Key word(s): Regulatory Approval/Product Launch
Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2

03-Aug-2022 / 07:50 CET/CEST
Disclosure of an inside...

Quelle: Börse Online RSS Feed

https://satsman.com?ref=resek&c=grow-your-armyvor 3 Stunden
Looking for Bitcoin Cash ambassadors to help us onboard more people into BCHvor 3 Stunden
Charity Actvor 3 Stunden
Bitcoin is helping build a historic tall ship in San Diegovor 4 Stunden
DO NOT OWN BONDS. DO NOT OWN THE DOLLAR.vor 4 Stunden
Fictional reservevor 4 Stunden
Why There’s Not Going to be a Class Action Lawsuit Against CoinKitevor 5 Stunden
After the 2028 halving we will get only 1.5625 BTC so after it more miner farms will quit in favor of ai. (Please read the entire post)vor 5 Stunden
I found a scam kindavor 6 Stunden
Here is where bitcoin ownership stands today:vor 7 Stunden

DGAP-Adhoc: Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis&#174;2

DGAP-Adhoc: Formycon announces FDA approval of FYB201/CIMERLITM1 (ranibizumab-eqrn) as a Biosimilar interchangeable with Lucentis®2